Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
14 February 2025
In the News
Brian Wheeler Joins Podcast to Discuss Legal Journey
Foley & Lardner LLP partner Brian Wheeler joined the Hsu Untied podcast to discuss his legal career.
14 February 2025
In the News
Pavan Agarwal Featured in Leadership Q&A – 'Reflecting our firm’s core values drives me to do my best'
Foley & Lardner LLP partner Pavan Agarwal is featured by Law.com for his career journey, legal practice, and leadership in the article, “How I Made Practice Group Chair: ‘Keep Listening and Keep Learning,’ Says Pavan Agarwal of Foley & Lardner.”
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."